Travis Carpenter was diagnosed with NF1 at 6 months. Years of visiting different specialists and trying different treatments did not yield the progress Travis’ parents and doctors were looking for. Read more about that part of the journey here. However, things started to turn around in November 2015, when Travis enrolled in the MEK-inhibitor AZD6244 (Selumetinib) clinical trial at the NIH.
While not yet a cure, Travis’ life has improved with enhanced mobility and better health. We asked Kelly, Travis’ mom, to tell us more about Travis’ progress and how it has impacted his life at the young age of 10.